Pharma Equity Group AS (OCSE:PEG) Other Current Liabilities: kr1.50 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharma Equity Group AS Other Current Liabilities?

Pharma Equity Group AS OCSE:PEG -2.05% Other Current Liabilities is kr1.50 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Pharma Equity Group AS's other current liabilities for the quarter that ended in Dec. 2025 was kr1.50 Mil.

Pharma Equity Group AS's quarterly other current liabilities declined from Dec. 2024 (kr1.57 Mil) to Jun. 2025 (kr0.59 Mil) but then increased from Jun. 2025 (kr0.59 Mil) to Dec. 2025 (kr1.50 Mil).

Pharma Equity Group AS's annual other current liabilities increased from Dec. 2023 (kr1.52 Mil) to Dec. 2024 (kr1.57 Mil) but then declined from Dec. 2024 (kr1.57 Mil) to Dec. 2025 (kr1.50 Mil).

Pharma Equity Group AS Other Current Liabilities Related Terms

Pharma Equity Group AS Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS Other Current Liabilities Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 0.00 1.52 1.57 1.50

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.52 2.26 1.57 0.59 1.50

Pharma Equity Group AS Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of kr1.50 Mil mean?
Pharma Equity Group AS (OCSE:PEG) has a Other Current Liabilities of kr1.50 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharma Equity Group AS.
Is Pharma Equity Group AS's Other Current Liabilities too high?
Pharma Equity Group AS's current Other Current Liabilities is kr1.50 Mil.
How does Pharma Equity Group AS's Other Current Liabilities compare to VRTX and REGN?
Pharma Equity Group AS's Other Current Liabilities of kr1.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pharma Equity Group AS. Pharma Equity Group AS's current Other Current Liabilities is kr1.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Other Current Liabilities of kr1.50 Mil. The current Other Current Liabilities is kr1.50 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Other Current Liabilities is kr1.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .